HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘This Is The Time’ For Industry To Advocate TPP Approval – PCPC

This article was originally published in The Rose Sheet

Executive Summary

The Trans-Pacific Partnership was high among the Personal Care Products Council’s priorities during its recent Lobby Day on Capitol Hill. The trade group’s Executive VP, Global Affairs Francine Lamoriello discussed the trade deal’s promise with the Rose Sheet while acknowledging the challenges it faces in the current political climate.

You may also be interested in...



Wildcard President Trump And The Prospects For Cosmetics Reg Reform

EWG maintains that “the result of the election has no effect whatsoever on the need for cosmetics reform,” but it remains to be seen how legislative proposals for increased oversight would be received by the president-elect, who has outlined plans for dramatically cutting perceived overregulation. Meanwhile, new leadership is likely to be appointed at FDA, and hopes dwindle regarding the Trans-Pacific Partnership.

Post-Brexit, EU Cosmetics Regulation Will Remain ‘Passport For Trade’

The future of cosmetics regulation in the UK may be among the least of uncertainties in the aftermath of Brexit.

FDA Among Regulatory Authorities Reeling From Brexit Bombshell

Commissioner Robert Califf says FDA has no firm plan but will “react to whatever happens” following the UK’s momentous decision to leave the EU. The European Medicines Agency also is taking a wait-and-see approach, while regulated industries brace for potential compliance, R&D and IP challenges in Brexit’s aftermath.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel